OncoZenge

The MASCC annual meeting is a premier gathering of healthcare professionals dedicated to improving the quality of life for cancer patients. Consistent with MASCC’s purpose the conference focuses on the latest advancements and best practices in cancer supportive care.

The conference will provide a unique opportunity for OncoZenge to meet Key Opinion Leaders from Europe and around the world, sharing plans for the continued development and anticipated market introduction of BupiZenge™. BupiZenge™ promises to offer patients suffering from cancer-induced oral pains significant pain relief and quality of life benefits compared to today’s inadequate standard of care.

Governments and healthcare has an increasing focus on early detection and treatment of cancer, as well as quality of life, as evidenced by the EU Mission on Cancer where one of the four primary objectives aim to significantly improve patients Quality of Life during treatment. Governments and healthcare also strive to limit the use of systemic opioids to reduce the burden on patients and society from the ‘opioid crisis’.

The overall theme of the conference is to ‘Empower People Impacted by Cancer and Living with Toxicities’. The program will cover:

-        Home Care and Extending Supportive Care at Home or Closer to Home
-        Management of Emerging Toxicities
-        Innovative Implementation of Supportive Care in Cancer
-        Quality Improvement in Supportive Care

The Chair of the Mucositis Study Group at MASCC, Dr. Paolo Bossi, a Medical Oncologist and Associate Professor at the Humanitas Cancer Center in Milan, Italy, also serves as a member of the OncoZenge Advisory Board.

“We are excited to particpate in the 2024 MASCC annual meeting and to connect with leading experts in our field,” said Stian Kildal, CEO at OncoZenge. “Our planning for the phase 3 clinical trial together with a partner is progressing well, and we are therefore able to share preliminary plans for the final development and market introduction of BupiZenge. As we take important steps towards the market, creating awareness, gathering support and feedback from Key Opinion Leaders becomes all the more important on our journey to offer cancer patients effective pain control. At the same time, future licensees will benefit from local references in the medical profession as they evaluate the commercial opportunity to partner with OncoZenge.”

BupiZenge™ - Potential to be the leading treatment for oral pain.

For additional information, please contact:
Stian Kildal, CEO, mobile: +46 76 115 3797, e-mail: stian.kildal@oncozenge.se

Certified Adviser
OncoZenge’s Certified Adviser is Redeye AB.

OncoZenge AB
Gustavslundsvägen 34, 167 51 Stockholm, Sweden

About OncoZenge
OncoZenge develops a novel, effective, safe and well-tolerated treatment for oral pain in conditions where currently available treatment options either do not achieve sufficient pain relief or are associated with significant side effects. BupiZenge™ is a new oral lozenge formulation of bupivacaine, an anaesthetic with decades of clinical experience. OncoZenge's lead indication is oral pain due to an inflammatory condition called oral mucositis that affects millions of patients receiving cancer treatment. Oral mucositis causes profound physical and psychological suffering, and is a large unmet medical need for an effective, opioid-sparing treatment option. BupiZenge™ has shown significantly better pain relief compared to standard of care in this indication in a Phase 2 trial.

OncoZenge has its headquarters in Stockholm, Sweden, and its share is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ.